Please login to the form below
Yescarta
This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.
Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
Yescarta is the first CAR T-cell therapy recommended for routine use on the NHS. ... The decision from NICE makes Yescarta the first chimeric antigen receptor (CAR) T-cell therapy to be recommended for routine use on the NHS.
Latest news
-
Kite’s CAR-T therapy Yescarta granted EC approval in second-line lymphoma
Additionally, Yescarta demonstrated a 2.5 fold increase in patients who were alive at two years without disease progression or need for additional cancer treatment versus SOC. ... Moreover, improvements in EFS with Yescarta were consistent across key
-
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
Yescarta (axicabtagene ciloleucel) reached $175m in relapsed/refractory large B-cell lymphoma and relapsed/refractory indolent follicular lymphoma in both the US and Europe.
-
BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel). ... Meanwhile, Yescarta is used to treat follicular lymphoma and is also approved in the US for the
-
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
After a median follow-up of two years, Yescarta showed a 60.2% improvement in event-free survival (EFS) compared to SOC. ... Yescarta has been instrumental in transforming outcomes for patients with third-line LBCL.
-
Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit
Gilead was also bolstered by sales of its cell therapy products, which jumped by 36% to $191m in the first quarter, with Yescarta bringing in $160m and Tecartus bringing in $31m.
More from news
Approximately 16 fully matching, plus 58 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
By Clive Glover. Since the approval of the first five gene or gene-modified cell therapies in the US – Luxturna, Yescarta, Tecartus, Kymriah and Zolgensma – this new technology has been evolving
-
Cortellis Drugs to Watch in 2020 report
as Kymriah and Yescarta.
-
25 Women Leaders in UK Healthcare (part 2)
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
years. Kymriah’s US list price is $475, 000 while Gilead’s rival drug, Yescarta, is priced at $373, 000 (with European prices substantially lower than this).
-
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging sign.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
PMHub
CHASE
We are a leading provider of outsourced commercial, medical and recruitment services to UK pharmaceutical, biotech and healthcare companies....
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
